A new study has found that many cases of high-risk nonmetastatic hormone-sensitive prostate cancer may be more advanced than previously thought.
Tag: Prostate Cancer
FDA Approvals in Oncology: October-December 2024
To help our readers keep track of the cancer therapies approved by the U.S. Food and Drug Administration (FDA), understand their impact for patients, and put them in context of the current therapeutic landscape, Cancer Research Catalyst provides a quarterly review of the latest approvals in oncology from the FDA. The FDA had a busy 2024, issuing… Continue reading FDA Approvals in Oncology: October-December 2024
Alternate definitions of adverse pathology to predict a very high risk of metastasis in men with intermediate‐ and low‐risk prostate cancer
Abstract Background Adverse pathology (AP) is often used as an intermediate end point for long-term outcomes in men with prostate cancer (PCa) who are active surveillance candidates. The association between a commonly used AP definition and long-term outcomes was tested, which identified definitions more strongly linked to a high risk of metastasis. Methods Data were… Continue reading Alternate definitions of adverse pathology to predict a very high risk of metastasis in men with intermediate‐ and low‐risk prostate cancer
Editors’ Picks, December 2024: Immunosuppression in the Lung, New Mathematical Models, and More
As we ring in 2025, Cancer Research Catalyst wishes you a very Happy New Year! May your 2025 be full of love, connection, and inspiration. As always, we love to keep you connected with inspiring cancer research by sharing this month’s editors’ picks from the 10 American Association for Cancer Research (AACR) journals. December’s holiday… Continue reading Editors’ Picks, December 2024: Immunosuppression in the Lung, New Mathematical Models, and More
[ASAP] Discovery of a Potent and Selective GSPT1 Molecular Glue Degrader for the Treatment of Castration-Resistant Prostate Cancer
MRI-first strategy for prostate cancer detection proves to be safe, study finds
There are several strategies for the early detection of prostate cancer. The first step is often a blood test for prostate-specific antigen (PSA). If PSA levels exceed a certain threshold, the next step typically involves taking a tissue sample for analysis. Another option is to use magnetic resonance imaging (MRI) to search for signs of… Continue reading MRI-first strategy for prostate cancer detection proves to be safe, study finds
A novel approach to combatting prostate cancer
New research by a team of Indiana University School of Medicine scientists and their collaborators has uncovered a novel vulnerability in prostate cancer animal models that starves prostate tumors of critical nutrients and stunts their growth, which could lead to the development of new treatments for the deadly disease. Led by IU School of Medicine’s Kirk… Continue reading A novel approach to combatting prostate cancer
Researchers find way to ‘starve’ prostate cancer tumors at the cellular level
Research has uncovered a vulnerability in prostate cancer animal models that starves prostate tumors of critical nutrients and stunts their growth, which could lead to the development of new treatments for the deadly disease.
Novel platinum complex shows strong antiproliferative effects with low toxicity in preclinical prostrate cancer models
Treating prostate cancer with novel platinum complex via targeting androgen receptor signaling
Prostate cancer, especially in advanced stages such as castration-resistant prostate cancer, is challenging to treat. Traditional therapies targeting androgen receptor (AR) signaling have limited efficacy. In a recent study, researchers investigated the potential of azolato-bridged dinuclear platinum(II) complexes, particularly 5-H-Y, as promising alternatives. Their findings highlight the complex’s ability to inhibit AR signaling and induce… Continue reading Treating prostate cancer with novel platinum complex via targeting androgen receptor signaling